Last updated: 11/07/2018 04:53:46
5ARI vs combo adherence in EP
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Adherence of patients taking 5ARI vs 5ARI + alpha blocker combination therapy in Enlarged Prostate
Trial description: GHO-09-0242: Adherence of patients taking 5ARI vs 5ARI + alpha blocker combination therapy in Enlarged Prostate
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
To describe the proportion of patients adherent to therapy with 5ARI monotherapy vs 5ARI plus AB.
Timeframe: Within the defined study period, claims will be assessed for a 1 year time period after the date of the first prescription claim for an AB or 5ARI related to a diagnosis of enlarged prostate.
Secondary outcomes:
To describe the length of time (days) that patients remained adherent to therapy with 5ARI monotherapy vs 5ARI plus AB.
Timeframe: Within the defined study period, claims will be assessed for a 1 year time period after the date of the first prescription claim for an AB or 5ARI related to a diagnosis of enlarged prostate.
Interventions:
Enrollment:
0
Primary completion date:
Not applicable
Observational study model:
Cohort
Time perspective:
Retrospective
Clinical publications:
Kruep E, Phillips E, Hogue SL, Eaddy MT . Early Symptom Improvement and Discontinuation of 5-Alpha Reductase Inhibitor (5ARI) Therapy in Patients with Benign Prostatic Hyperplasia (BPH). Ann Pharmacother. 2014;48:343-348.
Medical condition
Prostatic Hyperplasia
Product
dutasteride
Collaborators
Not applicable
Study date(s)
February 2009 to July 2009
Type
Observational
Phase
4
Participation criteria
Sex
Male
Age
50+ years
Accepts healthy volunteers
none
- Male patients aged 50 years or greater with at least one medical claim of enlarged prostate during the study period and at least one prescription claim of a 5ARI with or without an AB. Patients were required to be continuously eligible for 6 months prior to and at least 6 months after their index prescription date.
- Patients with prostate or bladder cancer; any prostate-related surgical procedure within 6 months prior to the index prescription date; prescription claim for finasteride indicative of male pattern baldness; less than 15 days of initial treatment; 5ARI initiated greater than 30 days after AB initiation; AB initiated any time after 5ARI therapy initiation for patients in the 5ARI monotherapy cohort
Inclusion and exclusion criteria
Inclusion criteria:
- Male patients aged 50 years or greater with at least one medical claim of enlarged prostate during the study period and at least one prescription claim of a 5ARI with or without an AB. Patients were required to be continuously eligible for 6 months prior to and at least 6 months after their index prescription date. -
Exclusion criteria:
- Patients with prostate or bladder cancer; any prostate-related surgical procedure within 6 months prior to the index prescription date; prescription claim for finasteride indicative of male pattern baldness; less than 15 days of initial treatment; 5ARI initiated greater than 30 days after AB initiation; AB initiated any time after 5ARI therapy initiation for patients in the 5ARI monotherapy cohort -
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2009-16-07
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website